about
Use of task-shifting to rapidly scale-up HIV treatment services: experiences from Lusaka, ZambiaModeling the impact of integrating HIV and outpatient health services on patient waiting times in an urban health clinic in ZambiaPregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African womenClinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.Strengthening health systems at facility-level: feasibility of integrating antiretroviral therapy into primary health care services in lusaka, zambiaAn evaluation of the performance and acceptability of three LED fluorescent microscopes in Zambia: lessons learnt for scale-up.Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.Impact of organizational factors on adherence to laboratory testing protocols in adult HIV care in Lusaka, ZambiaRapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trialOpt-out provider-initiated HIV testing and counselling in primary care outpatient clinics in ZambiaThe high burden of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public health alertScreening for tuberculosis and testing for human immunodeficiency virus in Zambian prisonsA model of tuberculosis screening for pregnant women in resource-limited settings using Xpert MTB/RIF.Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial.Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations.Does provider-initiated counselling and testing (PITC) strengthen early diagnosis and treatment initiation? Results from an analysis of an urban cohort of HIV-positive patients in Lusaka, Zambia.Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa.Integrating HIV treatment with primary care outpatient services: opportunities and challenges from a scaled-up model in Zambia.Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia.Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trialAdherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, ZambiaBurnout and use of HIV services among health care workers in Lusaka District, Zambia: a cross-sectional study.CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy.Tuberculosis and HIV control in sub-Saharan African prisons: "thinking outside the prison cell".Tuberculosis diagnostic technology: an African solution … think rats.High prevalence of tuberculosis in newly enrolled HIV patients in Zambia: need for enhanced screening approach.Integrating active tuberculosis case finding in antenatal services in Zambia.Derivation of a tuberculosis screening rule for sub-Saharan African prisons.Neurosyphilis and stroke in a patient with antibodies to the human immunodeficiency virus.
P50
Q21254567-FF1FB8D0-AEB4-4F0A-9A21-27241F0126C3Q28730428-3A409383-98E0-466D-BD9D-EB3965F3FA25Q33753930-8BCCE9A5-5BD2-4298-9846-EBBA1E7ECCDAQ33797142-8838CAE2-2B8B-487C-A4BB-440A32B2CAD1Q33820144-5B7DE588-32C2-4CEA-B4B7-3690D3C916C9Q33991625-D932A671-ACB7-4917-B488-942C0EAAEFC0Q34071815-DA49C98C-EA9A-4D68-8BDD-BB1BF6CD6A5EQ34244796-BE857067-AF74-467B-ADD5-15E173812E02Q34253803-A598D80B-B07E-4EB3-BC24-A8BB96F1BFCCQ34556854-6F5DD7A8-F11E-400C-A92E-3F25AAF2D12AQ34792200-14DE102D-B228-4456-A0FE-E8AECE251832Q34946070-C379DCFD-ED78-4239-926E-7E8BD4469E1BQ34962152-C21BBA9F-F7CA-461F-B5A4-422FECDF975FQ35119993-18E9440B-2F24-4A8C-98D3-5712B079CF3AQ35294823-8A60E371-E5C5-4157-9D0F-65ADC366B960Q35630400-E72098D0-D480-4ED0-95AE-7F1C328DBBF5Q35883654-0FB3A596-8B5E-4020-8AFC-179F0C560B63Q35890799-551E8ECC-70C7-4334-9E6C-8935782C2C54Q35941348-129A85ED-854F-49BC-90BE-127A366641D3Q36386776-829229D7-A88F-4356-ABC0-32F065F8456BQ36556975-14F2D043-1E89-4D52-B2C0-4EDF8060694BQ36969338-E7100380-85FB-4B1E-BB76-41FEEBF56E57Q37113579-3F15EAEB-3D5B-497E-902C-730C2E0AC01AQ37114698-0C1A545E-0771-4407-AE06-FCDE38517776Q37209897-B9A13189-6E75-462A-BE32-8D46ECDB9AFDQ37272656-27CB6456-201D-49CE-A47E-BE534CD5F1D4Q37325907-1EA68408-A1A6-49D7-8B05-9B4D713975AEQ37355638-89D0547A-5605-4DBC-B97C-E6CE7EEFEEC4Q38417263-BE293C2D-B46D-4733-966F-00490C57B25DQ40063213-3EFE8526-0B2E-4852-B74A-8EF7F139466EQ40097723-FB0508EC-F653-4250-9FE2-1E00C03945C8Q41594571-EE6268B5-B057-4EE1-9CA2-F98E79EBD1C1Q42211991-0E9C4025-4ECA-4E44-A9D0-BED7108EE0D7Q43581552-A4559906-4D9F-4624-8891-62E1F72ABB33
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stewart Reid
@ast
Stewart Reid
@en
Stewart Reid
@es
Stewart Reid
@nl
Stewart Reid
@sl
type
label
Stewart Reid
@ast
Stewart Reid
@en
Stewart Reid
@es
Stewart Reid
@nl
Stewart Reid
@sl
altLabel
Stewart E. Reid
@en
prefLabel
Stewart Reid
@ast
Stewart Reid
@en
Stewart Reid
@es
Stewart Reid
@nl
Stewart Reid
@sl
P108
P106
P1153
14065064500
P21
P31
P496
0000-0001-7779-4820